ArticleAmerican journal of translational research2016
MicroRNA-134 functions as a tumor suppressor gene in gastric cancer.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- miRNAs Participate in the Regulation of Oxidative Stress-Related Gene Expression in Endometrioid Endometrial Cancer.International journal of molecular sciences · 2022Article
- The microRNA miR-134-5p induces calcium deposition by inhibiting histone deacetylase 5 in vascular smooth muscle cells.Journal of cellular and molecular medicine · 2020Article
- Review
- Mechanism of inhibiting proliferation of hepatocellular carcinoma Hepa1-6 cells by embryonic stem cell-conditioned medium.Experimental and therapeutic medicine · 2020Article
- Global Analysis of miRNA Signature Differentially Expressed in Insulin-resistant Human Hepatocellular Carcinoma Cell Line.International journal of medical sciences · 2020Article
- Mechanism of microRNA-431-5p-Archives of medical science : AMS · 2019Article
- From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.Cancer biology & medicine · 2019Article
- Expression profile of circulating microRNAs in the Correa pathway of progression to gastric cancer.United European gastroenterology journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MiR-134 can function as an oncogene or a tumor suppressor gene depending on cell type. However, the function of miR-134 in gastric cancer remains unclear to date. This study aims to evaluate the function of miR-134 in gastric cancer and investigate its effect on the sensitivity of gastric cancer cells to 5-FU. The expression of miR-134 assayed by real-time PCR was significantly lower in gastric cancer tissues than in noncancerous tissues. Over-expression of miR-134 significantly inhibited the proliferation and growth in vivo, as well as promoted the apoptosis of gastric cancer cells by targeting KRAS. Finally, the up-regulation of miR-134 enhanced the sensitivity of gastric cancer cells to 5-FU. In conclusion, miR-134 suppresses tumor development in gastric cancer by targeting KRAS and enhances cell sensitivity to 5-FU. Our results encourage researchers to use 5-FU in combination with miR-134 to treat gastric cancer.
Indexed as
Identifiers
27830015PMC5095324W2566237707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.